ASH 2014 | ASH 2014: Phase II SPRINT study of lenalidomide in relapsed/refractory mantle cell lymphoma

Marek Trněný

Prof Marek Trněný (Charles University Hospital, Prague, Czech Republic) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the phase 2 SPRINT (MCL-002) study of lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma, including the study design, efficacy and safety endpoints, and conclusions

Share this video  
Similar topics
Related videos
1:15
Clinical impact of ATM and TP53 mutations in mantle cell lymphoma
Jitka Malčíková
1:58
Should we transplant or not in frontline therapy for MCL?
Tycel Phillips
2:10
MANTLE-FIRST results: outcomes in R/R younger MCL by therapy type
Umberto Vitolo
3:58
Mantle cell lymphoma update: changing times & latest news
Simon Rule
1:03
IR plus R-HCVAD/R-MTX efficacious for young MCL in the first-line
Preetesh Jain
Mantle Cell Lymphoma
Lenalidomide
SPRINT
ASH 2014
5th December 2015
More from Marek Trněný
Improving outcomes for R/R DLBCL with polatuzumab vedotin
Treating mantle cell lymphoma earlier in the disease course
A question of age: how should elderly DLBCL patients be treated?
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals